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editorials
MEK Inhibitors for the Treatment of Low-Grade
Serous Ovarian Cancer: Expanding Therapeutic
Options for a Rare Ovarian Cancer Subtype
David M. Gershenson, MD1; Charlie Gourley, MBChB, PhD2; and James Paul, BSc3
The introduction of the binary grading system for
ovarian serous carcinoma in 2004, replacing tradi-
tional three-tier grading systems, and its subsequent
acceptance into the WHO classification system a de-
cade later led to a remarkable acceleration in studies of
low-grade serous ovarian carcinoma (LGSOC).1,2 Early
observational studies identified the demographic and
clinical characteristics of LGSOC compared with high-
grade serous ovarian carcinoma (HGSOC), including
its rarity (LGSOC comprises , 10% of all serous
carcinomas), younger age at diagnosis, relative che-
motherapy resistance, responsiveness to endocrine
therapy, and prolonged overall survival.3-6 Similar to
those with HGSOC, most patients present with ad-
vanced disease, and . 70% relapse.3,7
Concomitantly, molecular biology investigations iden-
tified its high frequency of estrogen and progesterone
receptor expression and the influence of the mitogen-
activated protein kinase (MAPK) signaling pathway
on its pathogenesis.5,8-20 LGSOC and HGSOC develop
along discrete developmental pathways, with LGSOC
having a high frequency of MAPK pathway mutations
and HGSOC having ubiquitous p53 mutations, DNA
repair defects, and copy number abnormalities.11-23
Multiple reports have indicated that KRAS mutations
occur in 16% to 44% of LGSOCs, BRAF muta-
tions in 2% to 20%, and NRAS mutations in up to
26%.11-21
As with most rare tumor subtypes, few effective thera-
peutic options exist for womenwith LGSOC. As noted, the
efficacy of chemotherapy is limited. Other options in-
clude endocrine therapy and bevacizumab.5,10,24-27 MEK
inhibitors are orally bioavailable, non-ATP competitive,
small-molecule inhibitors of MEK1/2. Once MEK in-
hibitors became available for clinical development, it was
logical to study them in LGSOC. The initial phase II trial
examined selumetinib in recurrent LGSOC.19 The ob-
jective response rate (ORR) was 15%, with 65% of
patients having stable disease, and median progression-
free survival (PFS) was 11.0 months. DNA from 34
patients was analyzed for KRAS and BRAF mutations.
There were two BRAF mutations (6%) and 14 KRAS
mutations (41%); however, no correlation between re-
sponse and mutational status was found.
Subsequently, two large randomized clinical trials of
MEK inhibitors in recurrent LGSOC were launched.
MILO/ENGOT-ov11, featured in the report by Monk
et al28 that accompanies this editorial, compared
binimetinib with physician’s choice of chemotherapy
(PCC). Between June 2013 and April 2016, 341 pa-
tients were accrued. GOG 0281 was a phase II/III trial
comparing trametinib with PCC (pegylated liposomal
doxorubicin or weekly paclitaxel, topotecan, letrozole,
or tamoxifen).29 Between February 2014 and April
2018, 260 patients were enrolled.
On the basis of an interim analysis of 303 patients,
enrollment in MILO was discontinued, because the
PFS hazard ratio (HR) crossed the predefined futility
boundary. Median PFS was 9.1 months for binimetinib
and 10.6 months for PCC by blinded independent
central review (BICR; HR, 1.21; P 5 .807); in the
updated analysis, corresponding median PFS times
were 10.4 and 11.5 months, respectively (HR, 1.15;
P5 .748). Conversely, GOG 0281 met its primary end
point, with a median PFS of 13.0 months for trametinib
and 7.2 months for PCC (HR, 0.48; P , .001). In the
MILO trial, the ORR by BICR was 16% for binimetinib
and 13% for PCC; however, in the updated analysis,
the ORR by local investigator assessment was 24% in
both groups. In GOG 0281, the ORRs were 26% and
6.2% for trametinib and PCC, respectively.
How do we interpret these disparate results? The MILO
trial failed to meet its primary end point, possibly
because of the better-than-anticipated outcome in the
PCC group, whereas GOG 0281 was the first positive
randomized trial in women with recurrent LGSOC.
There are potential explanations to consider, while
keeping in mind the limitations of cross-study com-
parisons. First, in the design of the MILO trial, median
PFS for PCC was estimated to be 7 months based on
two retrospective studies, and the design aimed to
detect an HR of 0.60, corresponding to a median PFS
of 11.7 months, in the binimetinib arm.4,5 Eligibility
was limited to # three lines of prior chemotherapy
regimens, with no limit to the number of lines of prior
hormonal therapy. As noted in Table 1 of the report by
Monk et al,28 only 28% of all patients in MILO received$
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By contrast, in the two studies used to estimate median PFS
in the PCC group, the proportions of patients who received at
least three prior systemic regimens were 62% (range, 1-11
prior regimens) and 56% (range, 1-14 prior regimens), respec-
tively.4,5 Moreover, 48.1% of patients in GOG 0281 had at
least three prior systemic regimens and thus represented
a more heavily pretreated and possibly poorer prognostic
group compared with that studied in MILO. Altogether, this
perhaps explains the better-than-expected outcome in the
MILOPCCarm,which in turnmayhavemade itmore difficult to
demonstrate a potential benefit of MEK inhibition in this study.
Another possible explanation is the difference in the PCC
arms, where GOG 0281 allowed letrozole and tamoxifen as
options. However, it should be noted that patients receiving
letrozole did well, and overall PFS results were statistically
significant even when patients receiving tamoxifen, who did
particularly poorly, were excluded. Alternatively, it may
simply be that trametinib has greater efficacy compared
with binimetinib in recurrent LGSOC. Fernández et al30
compared four different MEK inhibitors (trametinib, selu-
metinib, binimetinib, and refametinib) in novel LGSOC
patient-derived cell lines and found trametinib to have the
greatest antiproliferative effects. A single dose of trametinib
had a greater impact on cellular proliferation than 10-fold
higher doses of the other drugs. It also had the greatest impact
on cellular viability and was most capable of inducing apo-
ptosis. Similar findings have been reported in lung cancer cell
lines and tumor models.31,32 Whether this preclinical supe-
riority translates into greater clinical efficacy has not been
directly tested. One might counter with the argument that the
MILO updated analysis of 341 patients revealed median PFS
by BICR of 10.4 months and ORR by local investigator as-
sessment of 24% for binimetinib, whichwere not that different
from results in GOG 0281 (ie, median PFS, 13.0 months;
ORR, 26%). However, the latter trial included a more heavily
pretreated group. It is also worth highlighting the fact that
76% of patients receiving binimetinib had grade$ 3 adverse
events, and 31% had adverse events leading to permanent
discontinuation of study drug. There were several rare but
serious adverse events, such as decreased ejection fraction
and retinal vein occlusion, underscoring the fact that MEK
inhibitors can be somewhat complicated to manage and
require careful monitoring.
Finally, what is the significance of the mutational analysis
in the MILO28 trial? The selumetinib trial failed to demon-
strate a correlation between KRAS/BRAF mutations and
ORR, and the mutational analysis for GOG 0281 is ongoing.
The authors note a putative association between KRAS
mutation status and response. Although this is interesting,
this observation must be considered hypothesis generating
at present. First, 47 mutations in total were examined, and
the single statistically significant result would be less im-
pressive after an appropriate adjustment for this number of
comparisons. It is also not clear that the association is
restricted to the binimetinib arm, because the corre-
sponding odds ratio in the PCC arm is of a similar mag-
nitude (3.40 v 2.13) and not obviously different, given the
overlap of the respective 95% CIs (95% CI, 1.53 to 7.66 v
0.67 to 7.81). Admittedly, the PCC result is not statistically
significant, but the sample size is 50% of that for bini-
metinib, with power correspondingly reduced. Although the
ORR for binimetinib in the KRAS-mutant group is an im-
pressive 44%, this is in the context of the updated local
response rate in all biomarker-assessed patients, which is
already high at 27% overall (Table 3 by Monk et al28), and
the fact that this subgroup was selected after examination
of multiple others as outlined previously.
It would have been interesting to have examined the
predictive value (in the sense of allowing selection between
binimetinib and PCC) of KRAS mutation status by esti-
mating the relative effect of binimetinib versus PCC in the
KRAS-mutant and wild-type groups separately and using
a test for interaction to determine whether these differed
significantly. We do understand that the numbers available
mean the power to detect even themost marked interaction
is heavily compromised, but nonetheless, this is the ap-
proach required to assess the predictive value of this
biomarker. This more generally emphasizes the difficulties
associated with exploratory retrospective analysis of pre-
dictive biomarkers in clinical trials and perhaps suggests
a requirement to more seriously consider prospectively
incorporating putative biomarkers into the design of trials
where this is feasible and scientifically justified.33
In summary, although not meeting its primary end point,
the MILO study demonstrates that MEK inhibition results in
disease control in a significant number of patients and is
a strategy that should be seriously considered in this dif-
ficult-to-treat disease. More importantly, although there are
questions still to be answered regarding the extent to which
various MAPK mutations confer MEK inhibitor sensitivity, it
is clear that the molecular biology of some LGSOCs results
in their addiction to this pathway and exceptional re-
sponses to MEK inhibition.34 Such outcomes may not be
achievable with standard-of-care chemotherapy. Mean-
while, the search for the optimal predictive biomarker for
MEK inhibitor sensitivity continues.
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